Combo therapy shows potential for melanoma, ovarian cancer

02/19/2008 | Yahoo!

A combination of a CTLA-4-blocking antibody and a GVAX cancer vaccine may be more effective in treating melanoma and advanced ovarian cancer than either treatment on its own, according to a U.S. study. Researchers reported that none of the patients who received the combination therapy experienced severe adverse reactions, while some found that their tumors had shrunk or stabilized.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC